via The New York Times, by Anahad O’Connor About one in 15 Americans is infected with oral human papillomavirus, a sexually transmitted virus that causes throat cancers, and the disease is especially common among men, new research shows. The research is the first major study to document the nationwide prevalence of oral human papillomavirus, or HPV, a Read More >>

via Positively Aware, by Gary Bucher, MD, FAAFP I have witnessed and taken part in the many changes in HIV care over the past 25 years. At the beginning of the epidemic, silence and fear was the name of the game. It took HIV activists taking control of their health care destiny to force the medical community Read More >>

via Medscape, by Nick Mulcahy In young men who have sex with men (MSM), the human papillomavirus (HPV) quadrivalent vaccine (Gardasil, Merck) reduced the rates of anal intraepithelial neoplasia (AIN), compared with placebo, according to an international team of investigators. The study on the vaccine was published in the October 27 issue of the New England Journal Read More >>

via The New England Journal of Medicine, by Joel M. Palefsky, M.D., Anna R. Giuliano, Ph.D., Stephen Goldstone, M.D., Edson D. Moreira, Jr., M.D., Carlos Aranda, M.D., Heiko Jessen, M.D., Richard Hillman, M.D., Daron Ferris, M.D., Francois Coutlee, M.D., Mark H. Stoler, M.D., J. Brooke Marshall, Ph.D., David Radley, M.S., Scott Vuocolo, Ph.D., Richard M. Haupt, M.D., Read More >>

via The New York Times, by Gardiner Harris Boys and young men should be vaccinated against human papillomavirus, or HPV, to protect against anal and throat cancers that can result from sexual activity, a federal advisory committee said Tuesday. The recommendation by the panel, the Advisory Committee on Immunization Practices of the Centers for Disease Control and Read More >>

via Infotech “The findings explain the results of a recent clinical trial showing that the anti-HIV drug tenofovir, when it is formulated as a vaginal gel, could reduce the risk of herpes simplex virus (HSV) infections — as well as HIV infections — in women. Tenofovir taken orally had been demonstrated to inhibit reproduction of HIV, but Read More >>

via Journal of the American Sexually Transmitted Diseases Association, by Gilbert, Mark MD*; Kwag, Michael BA*; Mei, Wendy BSc†; Rank, Claudia MPH*‡; Kropp, Rhonda MSc‡; Severini, Alberto MD‡; van Niekerk, Dirk MD§; Zhou, Chen MD§; Press, Natasha MD¶; Ogilvie, Gina MD*; Wong, Tom MD‡; the ManCount Study Team  Background: Inclusion of self-collected rectal swabs (SCRS) into existing Read More >>

via Medpage Today A vaccine against human papillomavirus (HPV) protects women against two strains of the virus that causes anal cancer, researchers reported. The vaccine (Cervarix) against HPV strains 16 and 18 offered “strong protection” against anal infection in a study whose main goal was to assess the efficacy of vaccination against cervical infection and pre-cancerous lesions, Read More >>

via AIDSmeds The antiretroviral (ARV) drug lopinavir (found in Kaletra) is able to kill cervical cells infected with the human papillomavirus (HPV)—cells that can go on to become cancerous—according to a study published online May 5 in the journal Antiviral Therapy. HPV is one of the most widely spread viruses in the world. Transmitted through sexual contact, Read More >>

Via Aidsmap, by Michael Carter Prevalence and incidence of high-grade pre-cancerous anal lesions in HIV-positive men who are taking antiretroviral therapy are high, Canadian investigators report in the online edition of Clinical Infectious Diseases. A low nadir CD4 cell count and infection with HPV types 16 and 18 were associated with an increased risk of developing high-grade Read More >>